Ghana has formally launched its medicinal cannabis licensing programme at a moment when new scientific research is expanding the therapeutic case for cannabinoids, adding economic urgency to a regulatory process that took years to reach implementation. Researchers at the Hebrew University of Jerusalem recently published findings showing that two non-psychoactive cannabis compounds, Cannabidiol (CBD) and

CBD and CBG, two non-intoxicating cannabis compounds, may help combat fatty liver disease by boosting liver energy reserves and restoring cellular cleanup systems. In the study, both compounds improved blood sugar control and reduced harmful lipids linked to fatty liver disease. Researchers say the findings point to a promising new plant-based approach to treating metabolic liver disorders.

The hemp-derived cannabis company founded by a board-certified pharmacist with a vast catalog of diverse products

“Federal policy must reflect evidence and science, not dispelled myths and tired stereotypes.” By Sasha Kalcheff-Korn, National Compassionate Care Council Recent federal action initiating a review of cannabis scheduling and signaling interest in expanding cannabinoid research reflects a growing willingness to examine how federal policy aligns with emerging evidence and real-world patient experience—but it also

Discussions on the overlooked potential of these powerful compounds are on the rise